Section 174 R&D capitalization for tech and life science companies

The House’s draft tax revision bill proposes temporary relief from Section 174 R&D capitalization rules, allowing life sciences and technology companies to immediately expense domestic R&D costs from 2025 to 2029. This change offers strategic tax planning opportunities and reduces compliance burdens for innovation-driven companies.

While President Trump has made numerous statements and promises regarding tax revision  as of yet there is no new law or policy legally in place. However, progress has been made with the House passing the budget reconciliation bill on May 22. The bill includes immediate expensing of domestic R&D costs starting in 2025 and will sunset again in 2029. If passed, this means that companies will be given the option to immediately expense R&D costs for four years before immediate expensing sunsets and reverts to required capitalization of R&D expenditures. As the bill moves through the Senate, we will be watching closely for any changes and will release additional guidance pending further updates.

Since the Tax Cuts and Jobs Act (TCJA) went into effect, one of the biggest concerns for technology and life science companies, stemming from the President’s first term, has been the Section 174 research and development (R&D) capitalization.

The TCJA includes numerous “sunset provisions,” legal provisions that automatically expire on a specified date. Perhaps the most significant for technology and life science companies included within the TCJA was its treatment of R&D costs. 

Starting in 2022, IRC Section 174 requires companies to capitalize R&D costs and amortize them over five years for domestic R&D and 15 years for international R&D. Prior to 2022, companies had the option to expense these costs in the year incurred. Section 174 capitalization has been, at times, a struggle to accurately track, and these rules have caused several technology and life sciences companies, who had never paid taxes before, to become taxpayers. 

With that being said, Section 174 compliance has had some positive impacts. The additional required procedures have encouraged clients who previously did not perform R&D credit studies because of the cumbersome tracking requirements to begin performing studies, as they are now required to monitor their R&D costs meticulously for Section 174 purposes anyway

Even if the tax law remains as is for taxpayers with domestic R&D, this will soon become much less of a burden. Once a company has five years of R&D capitalized, it will also be amortizing five years' worth of R&D costs. After the five-year period, any incremental R&D capitalized should be largely offset by the amortization of the five years’ worth of R&D costs previously capitalized.

What does CohnReznick think?

The immediate expensing of R&D costs in 2025 will result in companies having amortization on three years of previously capitalized R&D costs (2022 through 2024). Additionally, companies will have the option to either capitalize or expense R&D costs immediately from 2025 through 2029. This approach does not provide an immediate benefit on prior period capitalized costs via the filing of a method change,  but it will serve as a planning mechanism for taxpayers to decide whether to continue capitalizing or expensing going forward.

Conversely, if the bill allows for a retroactive change, it would enable a potential one-year benefit by expensing previously capitalized R&D costs and expensing R&D costs going forward. Any change in R&D capitalization presents an opportunity for tax planning, depending on the specific circumstances of the company.

Contact us to discuss potential tax planning strategies with respect to tax revision.

OUR PEOPLE

Subject matter expertise

View All Specialists
Seth Sherer

Seth Sherer

Senior Manager, Tax

Looking for the full list of our dedicated professionals here at CohnReznick?

Close

Contact

Let’s start a conversation about your company’s strategic goals and vision for the future.

Please fill all required fields*

Please verify your information and check to see if all require fields have been filled in.

Please select job function
Please select job level
Please select country
Please select state
Please select industry
Please select topic

Related services

Our solutions are tailored to each client’s strategic business drivers, technologies, corporate structure, and culture.

Any advice contained in this communication, including attachments and enclosures, is not intended as a thorough, in-depth analysis of specific issues. Nor is it sufficient to avoid tax-related penalties. This has been prepared for information purposes and general guidance only and does not constitute legal or professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice specific to, among other things, your individual facts, circumstances and jurisdiction. No representation or warranty (express or implied) is made as to the accuracy or completeness of the information contained in this publication, and CohnReznick, its partners, employees and agents accept no liability, and disclaim all responsibility, for the consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.